{
    "2020-09-07": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Novartis post hoc analysis shows high-dose Enerzair速 Breezhaler速 reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings",
                "features": {
                    "keywords": [
                        "Novartis",
                        "high-dose",
                        "Enerzair速 Breezhaler速",
                        "asthma exacerbations",
                        "IRIDIUM study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}